[{"id":"b27e5854-9657-4b24-a83c-b4bf33177792","acronym":"","url":"https://clinicaltrials.gov/study/NCT03884556","created_at":"2021-01-18T19:08:40.399Z","updated_at":"2025-02-25T16:15:48.685Z","phase":"Phase 1","brief_title":"TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers","source_id_and_acronym":"NCT03884556","lead_sponsor":"Trishula Therapeutics, Inc.","biomarkers":" ENTPD1","pipe":" | ","alterations":" ENTPD1 expression","tags":["ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ENTPD1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • docetaxel • albumin-bound paclitaxel • eltivutabart (TTX-030)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 04/10/2019","start_date":" 04/10/2019","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 09/29/2023","study_completion_date":" 09/29/2023","last_update_posted":"2023-10-04"}]